Pharmaceutical company Eli Lilly has announced that its drug Cyramza designed for treating patients with cancer of the liver, really extends the life of patients with this form of cancer.
This became clear after the last stage of clinical trials. About 4 years ago, pilot clinical trials of Cyramza failed. Then to show that the drug prolongs lives of patients with cancer of the liver failed, although it was shown that tumor size decreased, and the condition of patients deteriorated more slowly.
In the U.S. Cyramza, a drug based on monoclonal antibody already approved for the treatment of gastric cancer, colorectal cancer and lung cancer. Now it was given to the patients suffering from hepatocellular carcinoma – the most common form of liver cancer.
To participate in the study were selected patients, tumors which did not respond to therapy with Nexavar (Nexavar), a drug from Bayer AG, or whose condition after such treatment has deteriorated. Currently Nexavar is the first-line drug for patients with liver cancer. All participants of the experiment were increased concentration of AFP, which indicates an unfavorable prognosis.
In clinical trials it was shown that Cyramza prolongs the life of patients with cancer of the liver, and slows the progression of the tumor. The company believes that even greater efficiency can be achieved by combining with Cyramza immunologicheskaja.